John A Bittl

List of Publications by Year in Descending Order

104 papers	11,560 citations	39 h-index	107 g-index
141 ext. papers	13,506 ext. citations	8.1 avg, IF	5.71 L-index

#	Paper	IF	Citations
104	Putting the 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization Into Practice: A Case Series.. *JACC: Case Reports*, **2022**, 4, 31-35	1.2	
103	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*, **2021**, CIR0000000000001039	16.7	15
102	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*, **2021**, CIR0000000000001038	16.7	23
101	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. *Journal of the American College of Cardiology*, **2021**,	15.1	42
100	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. *Journal of the American College of Cardiology*, **2021**, 79, 197-197	15.1	12
99	Dialysis access intervention: Techniques for the interventional cardiologist. *Progress in Cardiovascular Diseases*, **2021**, 65, 84-88	8.5	1
98	Antithrombotic Therapy after Acute Coronary Syndromes. *New England Journal of Medicine*, **2021**, 384, 1872-1873	59.2	
97	Multivessel Percutaneous Coronary Intervention During ST-Elevation Myocardial Infarction-A Dickensian Debate That Never Ends. *JAMA Cardiology*, **2021**, 6, 580-581	16.2	
96	Integrating the ABC-Bleeding Risk Score Into Practice. *JAMA Network Open*, **2020**, 3, e2016126	10.4	
95	Bayes Factor Meta-Analysis of the Mortality Claim for Peripheral Paclitaxel-Eluting Devices. *JACC: Cardiovascular Interventions*, **2019**, 12, 2528-2537	5	3
94	An Update on Radial Artery Access and Best Practices for Transradial Coronary Angiography and Intervention in Acute Coronary Syndrome: A Scientific Statement From the American Heart Association. *Circulation: Cardiovascular Interventions*, **2018**, 11, e000035	6	212
93	Treatment Strategies for Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease: Is Staged PCI Truly the Best Option?. *JACC: Cardiovascular Interventions*, **2017**, 10, 206-207	5	
92	Bayesian Analysis: A Practical Approach to Interpret Clinical Trials and Create Clinical Practice Guidelines. *Circulation: Cardiovascular Quality and Outcomes*, **2017**, 10,	5.8	32
91	PCI Strategies in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Artery Disease. *Journal of the American College of Cardiology*, **2016**, 68, 1066-81	15.1	41
90	Extended Dual Antiplatelet Therapy in Patients With Prior Myocardial Infarction. *JAMA Cardiology*, **2016**, 1, 629-30	16.2	1
89	How long should dual antiplatelet therapy be used in diabetic patients after implantation of drug-eluting stents?. *Current Opinion in Cardiology*, **2016**, 31, 677-682	2.1	0
88	Meta-analysis of randomized controlled trials comparing percutaneous coronary intervention with aspiration thrombectomy Vs. Conventional percutaneous coronary intervention during ST-segment elevation myocardial infarction. *Catheterization and Cardiovascular Interventions*, **2016**, 87, 1203-10	2.7	7

87	The Tradeoff Between Shorter and Longer Courses of Dual Antiplatelet Therapy After Implantation of Newer Generation Drug-Eluting Stents. *Current Cardiology Reports*, **2016**, 18, 8	4.2	1
86	2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of	15.1	491
85	2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Journal of the American College of Cardiology*, **2016**, 68, 1082-115	15.1	856
84	Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on	16.7	46
83	Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Journal of the American College of Cardiology*, **2016**, 68, 1116-39	15.1	125
82	Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction. *JAMA Cardiology*, **2016**, 1, 226-7	16.2	2
81	2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for	1.5	71
80	Percutaneous coronary interventions in the diabetic patient: where do we stand?. *Circulation: Cardiovascular Interventions*, **2015**, 8, e001944	6	22
79	Outcomes after multivessel or culprit-Vessel intervention for ST-elevation myocardial infarction in patients with multivessel coronary disease: a Bayesian cross-design meta-analysis. *Catheterization and Cardiovascular Interventions*, **2015**, 86 Suppl 1, S15-22	2.7	11
78	Factors Affecting Bleeding and Stent Thrombosis in Clinical Trials Comparing Bivalirudin With Heparin During Percutaneous Coronary Intervention. *Circulation: Cardiovascular Interventions*, **2015**, 8, e002789	6	8
77	Bayesian Inference Supports the Use of Bypass Surgery Over Percutaneous Coronary Intervention To Reduce Mortality in Diabetic Patients with Multivessel Coronary Disease. *International Journal of Statistics in Medical Research*, **2015**, 4, 26-34	3	2
76	2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American	15.1	497
75	2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for	16.7	361
74	Response to letters regarding article, "Bayesian methods affirm the use of percutaneous coronary intervention to improve survival in patients with unprotected left main coronary artery disease". *Circulation*, **2014**, 129, e309	16.7	
73	Family presence during catheterization procedures. *Catheterization and Cardiovascular Interventions*, **2014**, 83, 341	2.7	1
72	Bayesian methods affirm the use of percutaneous coronary intervention to improve survival in patients with unprotected left main coronary artery disease. *Circulation*, **2013**, 127, 2177-85	16.7	66
71	Chelation therapy and cardiovascular outcomes. *JAMA - Journal of the American Medical Association* , **2013**, 310, 430-1	27.4	2
70	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *Catheterization and*	2.7	81

69	Interventions for Failing Hemodialysis Access **2013**, 421-429		
68	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *Journal of the American College of Cardiology*, **2011**, 58, e123-210	15.1	1703
67	2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. *Journal of the American College of Cardiology*, **2011**, 58, e123-210	15.1	531
66	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *Circulation*, **2011**, 124, e574-651	16.7	1039
65	2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*, **2011**, 124, 2610-42	16.7	345
64	Economic analysis of angiography and preemptive angioplasty to prevent hemodialysis-access thrombosis. *Catheterization and Cardiovascular Interventions*, **2010**, 75, 14-21	2.7	20
63	Catheter interventions for hemodialysis fistulas and grafts. *JACC: Cardiovascular Interventions*, **2010**, 3, 1-11	5	73
62	Adaptive remodeling of hypoplastic hemodialysis fistulas salvaged with angioplasty. *Catheterization and Cardiovascular Interventions*, **2009**, 73, 974-8	2.7	7
61	Venous rupture during percutaneous treatment of hemodialysis fistulas and grafts. *Catheterization and Cardiovascular Interventions*, **2009**, 74, 1097-101	2.7	28
60	Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. *American Journal of Cardiology*, **2007**, 100, 1364-9	3	268
59	Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. *American Heart Journal*, **2006**, 152, 157-63	4.9	12
58	Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial. *American Heart Journal*, **2006**, 152, 149-54	4.9	24
57	Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. *European Heart Journal*, **2005**, 26, 2396-403	9.5	21
56	The truth about activated clotting time measurements. *Catheterization and Cardiovascular Interventions*, **2005**, 65, 338-9	2.7	1
55	Prospective assessment of hemodialysis access patency after percutaneous intervention: Cox proportional hazards analysis. *Catheterization and Cardiovascular Interventions*, **2005**, 66, 309-15	2.7	15
54	Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. *JAMA - Journal of the American Medical Association*, **2004**, 292, 696-703	27.4	304
53	Concomitant peripheral arterial disease and coronary artery disease: therapeutic opportunities. *Circulation*, **2004**, 109, 3136-44	16.7	25
52	Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). *American Journal of Cardiology*, **2004**, 93, 1092-6	3	183

51	Meta-analysis of randomized trials of percutaneous transluminal coronary angioplasty versus atherectomy, cutting balloon atherotomy, or laser angioplasty. *Journal of the American College of Cardiology*, **2004**, 43, 936-42	15.1	86
50	Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. *American Journal of Cardiology*, **2003**, 92, 919-23	3	73
49	Cutting balloon angioplasty for undilatable venous stenoses causing dialysis graft failure. *Catheterization and Cardiovascular Interventions*, **2003**, 58, 524-6	2.7	36
48	Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. *Journal of the American College of Cardiology*, **2003**, 41, 386-93	15.1	81
47	Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. *JAMA - Journal of the American Medical Association*, **2003**, 289, 853-63	27.4	896
46	Percutaneous therapy of dialysis access failure. *Catheterization and Cardiovascular Interventions*, **2002**, 56, 157-61	2.7	7
45	Coronary flow velocity and disturbed flow predict adverse clinical outcome after coronary angioplasty. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2002**, 22, 1334-40	9.4	14
44	From confusion to clarity: Direct thrombin inhibitors for patients with heparin-induced thrombocytopenia. *Catheterization and Cardiovascular Interventions*, **2001**, 52, 473-5	2.7	2
43	Cardiovascular disease in dialysis patients: double trouble. *Catheterization and Cardiovascular Interventions*, **2001**, 54, 464-5	2.7	
42	Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. *American Heart Journal*, **2001**, 142, 952-9	4.9	282
41	Cholesterol embolization syndrome: unifying principles. *Catheterization and Cardiovascular Interventions*, **2000**, 51, 326-7	2.7	5
40	Clinical outcomes of bivalirudin for ischemic heart disease. *Circulation*, **1999**, 100, 2049-53	16.7	86
39	No-touch technique for reducing aortic wall trauma during renal artery stenting. *Catheterization and Cardiovascular Interventions*, **1999**, 46, 245-8	2.7	64
38	Creatine kinase leaks, myocardial necrosis, and prognosis after percutaneous coronary interventions. *Catheterization and Cardiovascular Interventions*, **1999**, 46, 303-4	2.7	1
37	Optimizing the benefits of renal artery stenting. *Catheterization and Cardiovascular Interventions*, **1999**, 47, 173-4	2.7	1
36	A safety net for saphenous vein graft perforations. *Catheterization and Cardiovascular Interventions*, **1999**, 48, 387	2.7	
35	Effect of transient abrupt vessel closure during otherwise successful angioplasty for unstable angina on clinical outcome at six months. Hirulog Angioplasty Study Investigators. *Journal of the American College of Cardiology*, **1999**, 33, 73-8	15.1	17
34	Effect of direct thrombin inhibition with Bivalirudin (Hirulog) on restenosis after coronary angioplasty. *American Journal of Cardiology*, **1998**, 82, 511-5	3	29

33	Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty. *American Journal of Cardiology*, **1998**, 82, 50P-56P	3	32
32	A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. Hirulog Angioplasty Study Investigators. *American Journal of Cardiology*, **1998**, 82, 43P-49P	3	36
31	Laser wire for crossing chronic total occlusions: "learning phase" results from the U.S. TOTAL trial. Total Occlusion Trial With Angioplasty by Using a Laser Wire. *Catheterization and Cardiovascular Diagnosis*, **1998**, 44, 235-43		10
30	Myonecrosis after revascularization procedures. *Journal of the American College of Cardiology*, **1998**, 31, 241-51	15.1	367
29	Antithrombotic therapy in patients undergoing coronary angioplasty. *Chest*, **1998**, 114, 728S-741S	5.3	36
28	Laser wire for crossing chronic total occlusions: learning phase results from the U.S. TOTAL trial **1998**, 44, 235		2
27	Bivalirudin compared with heparin during coronary angioplasty for thrombus-containing lesions. *Journal of the American College of Cardiology*, **1997**, 30, 1264-9	15.1	17
26	Excimer laser coronary angioplasty: the New Approaches to Coronary Intervention (NACI) experience. *American Journal of Cardiology*, **1997**, 80, 99K-105K	3	23
25	Advances in coronary angioplasty. *New England Journal of Medicine*, **1996**, 335, 1290-302	59.2	206
24	Coronary stent occlusion: thrombus horribilis. *Journal of the American College of Cardiology*, **1996**, 28, 368-70	15.1	25
23	Excimer laser angioplasty: focus on total occlusions. *American Journal of Cardiology*, **1996**, 78, 823-4	3	4
22	Excimer laser-facilitated angioplasty for undilatable coronary narrowings. *American Journal of Cardiology*, **1996**, 78, 1045-6	3	37
21	Analysis and comparison of operator-specific outcomes in interventional cardiology. From a multicenter database of 4860 quality-controlled procedures. *Circulation*, **1996**, 93, 431-9	16.7	53
20	The changing profile of patient selection, procedural techniques, and outcomes in excimer laser coronary angioplasty. Participating Investigators of the Percutaneous Excimer Laser Coronary Angioplasty Registry. *Journal of Interventional Cardiology*, **1995**, 8, 653-60	1.8	6
19	Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. *New England Journal of Medicine*, **1995**, 333, 764-9	59.2	427
18	Effect of intracoronary saline infusion on dissection during excimer laser coronary angioplasty: a randomized trial. The Percutaneous Excimer Laser Coronary Angioplasty (PELCA) Investigators. *Journal of the American College of Cardiology*, **1995**, 26, 1264-9	15.1	79
17	Antithrombotic therapy in patients undergoing coronary angioplasty. *Chest*, **1995**, 108, 486S-501S	5.3	34
16	Orthodeoxia-platypnea due to intracardiac shunting--relief with transcatheter double umbrella closure. *Catheterization and Cardiovascular Diagnosis*, **1995**, 36, 247-50		55

15	Length of hospital stay and complications after percutaneous transluminal coronary angioplasty. Clinical and procedural predictors. Heparin Registry Investigators. *Circulation*, **1995**, 92, 311-9	16.7	42
14	Early and late quantitative angiographic results of vein graft lesions treated by excimer laser with adjunctive balloon angioplasty. *Circulation*, **1995**, 92, 348-56	16.7	26
13	Excimer Laser Coronary Angioplasty. *Cardiology Clinics*, **1994**, 12, 585-593	2.5	
12	Mitral valve balloon dilatation: long-term results. *Journal of Cardiac Surgery*, **1994**, 9, 213-7	1.3	1
11	Acute complications of excimer laser coronary angioplasty: a detailed analysis of multicenter results. Coinvestigators of the U.S. and European Percutaneous Excimer Laser Coronary Angioplasty (PELCA) Registries. *Journal of the American College of Cardiology*, **1994**, 23, 1305-13	15.1	72
10	Analysis of late lumen narrowing after excimer laser-facilitated coronary angioplasty. *Journal of the American College of Cardiology*, **1994**, 23, 1314-20	15.1	28
9	Coronary artery perforation during excimer laser coronary angioplasty. The percutaneous Excimer Laser Coronary Angioplasty Registry. *Journal of the American College of Cardiology*, **1993**, 21, 1158-65	15.1	127
8	Directional coronary atherectomy versus balloon angioplasty. *New England Journal of Medicine*, **1993**, 329, 273-4	59.2	21
7	Relation between clinical presentation and angiographic findings in unstable angina pectoris, and comparison with that in stable angina. *American Journal of Cardiology*, **1993**, 72, 544-50	3	55
6	Transcatheter umbrella closure of valvular and paravalvular leaks. *Journal of the American College of Cardiology*, **1992**, 20, 1371-7	15.1	166
5	Wire-guided excimer laser coronary angioplasty: instrument selection, lesion characterization, and operator technique. *Journal of Interventional Cardiology*, **1992**, 5, 275-91	1.8	2
4	Clinical success, complications and restenosis rates with excimer laser coronary angioplasty. The Percutaneous Excimer Laser Coronary Angioplasty Registry. *American Journal of Cardiology*, **1992**, 70, 1533-9	3	121
3	Successful treatment of an excimer laser-associated coronary artery perforation with the Stack perfusion catheter. *Catheterization and Cardiovascular Diagnosis*, **1991**, 22, 118-23		20
2	Peak left ventricular pressure during percutaneous aortic balloon valvuloplasty: clinical and echocardiographic correlations. *Journal of the American College of Cardiology*, **1989**, 14, 135-42	15.1	5
1	Biochemical responses of myocardial cells in culture to oxygen and glucose deprivation. *Biochemical and Biophysical Research Communications*, **1974**, 59, 749-56	3.4	28